Quick Answer
Centessa Pharmaceuticals plc reported Operating Income Loss of -$207.69 million for the year ending 2025.
- Centessa Pharmaceuticals plc showed a decrease of -3.3% in Operating Income Loss from 2024 to 2025.
- This data is from Centessa Pharmaceuticals plc's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$2.13 million | Q3 2020: -$2.12 million | Q1 2021: -$236.19 million | Q2 2021: -$41.29 million | Q3 2021: -$38.31 million | Q1 2022: -$53.22 million | Q2 2022: -$68.41 million | Q3 2022: -$49.03 million | Q1 2023: -$48.88 million | Q2 2023: -$47.02 million | Q3 2023: -$40.21 million | Q1 2024: -$36.09 million | Q2 2024: -$43.98 million | Q3 2024: -$46.41 million | Q1 2025: -$30.78 million | Q2 2025: -$54.65 million | Q3 2025: -$53.79 million.
- Over the full 8 years of available data (2019 to 2025), Centessa Pharmaceuticals plc's Operating Income Loss has declined by 4,010.3%.
- Historical annual values: Fiscal year 2025: -$207.69 million | Fiscal year 2024: -$201.06 million | Fiscal year 2023: -$171.28 million | Fiscal year 2022: -$212.26 million | Fiscal year 2021: -$374.08 million | Fiscal year 2021: -$783.0 thousand | Fiscal year 2020: -$10.44 million | Fiscal year 2019: -$5.05 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: